Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional Assessment

被引:63
作者
Lupon, Josep [1 ,3 ]
de Antonio, Marta [1 ,3 ]
Galan, Amparo [2 ]
Vila, Joan [4 ,5 ]
Zamora, Elisabet [1 ,3 ]
Urrutia, Agustin [1 ,3 ]
Bayes-Genis, Antoni [1 ,3 ]
机构
[1] Hosp Badalona Germans Trias & Pujol, Heart Failure Unit, Badalona 08916, Spain
[2] Hosp Badalona Germans Trias & Pujol, Serv Biochem, Badalona 08916, Spain
[3] Autonomous Univ Barcelona, Dept Med, Barcelona, Spain
[4] Hosp del Mar, Res Inst, Inflammatory & Cardiovasc Dis Programme, IMIM, Barcelona, Spain
[5] CIBER Epidemiol & Publ Hlth, Madrid, Spain
关键词
NATRIURETIC PEPTIDE; MULTIMARKER APPROACH; PROGNOSIS; DIAGNOSIS; MORTALITY; PLASMA; SURVIVAL; PROBNP; ASSAY; BNP;
D O I
10.1016/j.mayocp.2012.09.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess an innovative multimarker strategy for risk stratification of death in a real-life ambulatory heart failure (HF) cohort. Patients and Methods: The study included 876 consecutive outpatients (median age, 70.3 years; left ventricular ejection fraction, 34%) between May 22, 2006, and July 7, 2010, prospectively followed up in a structured HF unit. A combination of biomarkers reflecting myocardial stretch (N-terminal pro-B-type natriuretic peptide [NT-proBNP]), myocyte injury (high-sensitivity cardiac troponin T [hs-cTnT]), and ventricular fibrosis and remodeling (high-sensitivity ST2 [hs-ST2]) were added to an assessment based on established mortality risk factors (age, sex, left ventricular ejection fraction, New York Heart Association functional class, diabetes mellitus, estimated glomerular filtration rate, ischemic etiology, sodium level, hemoglobin level, and pharmacologic treatment). Results: During median follow-up of 41.4 months, 311 patients died. The combined addition of hs-cTnT and hs-ST2 to the model yielded good measurements of performance (C statistic, 0.789; Bayesian information criterion, 3611; integrated discrimination improvement, 4.1 [95% CI, 2.5-5.6]; and net reclassification index, 13.9% [95% CI, 6.2-21.6]). Reclassification did not significantly benefit after NT-proBNP addition into the full model; some indices even worsened with all 3 biomarkers. Separate addition of NT-proBNP provided prognostic discrimination only in the subgroup of patients with either hs-cTnT or hs-ST2 levels below the cutoff points (hazard ratio, 2.97; 95% CI, 2.24-9.39; P<.001). Conclusion: A multimarker strategy seems useful for stratifying risk in chronic HF. However, NT-proBNP in addition to the new-generation biomarkers hs-cTnT and hs-ST2 had a limited effect on risk stratification. (c) 2013 Mayo Foundation for Medical Education and Research square Mayo Clin Proc. 2013;88(3):234-243
引用
收藏
页码:234 / 243
页数:10
相关论文
共 28 条
[1]   Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure [J].
Bayes-Genis, Antoni ;
de Antonio, Marta ;
Galan, Amparo ;
Sanz, Hector ;
Urrutia, Agustin ;
Cabanes, Roser ;
Cano, Lucia ;
Gonzalez, Beatriz ;
Diez, Cristanto ;
Pascual, Teresa ;
Elosua, Roberto ;
Lupon, Josep .
EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (01) :32-38
[2]   Predicting mortality in patients with heart failure: a pragmatic approach [J].
Bouvy, ML ;
Heerdink, ER ;
Leufkens, HGM ;
Hoes, AW .
HEART, 2003, 89 (06) :605-609
[3]   Biomarkers in heart failure [J].
Braunwald, Eugene .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (20) :2148-2159
[4]   IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex [J].
Chackerian, Alissa A. ;
Oldham, Elizabeth R. ;
Murphy, Erin E. ;
Schmitz, Jochen ;
Pflanz, Stefan ;
Kastelein, Robert A. .
JOURNAL OF IMMUNOLOGY, 2007, 179 (04) :2551-2555
[5]  
Chakeabarti S, 2010, J CARD FAIL, V16, pS53, DOI 10.1016/j.cardfail.2010.04.004
[6]   Natriureettic peptides [J].
Daniels, Lori B. ;
Maisel, Alan S. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (25) :2357-2368
[7]   Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure [J].
de Antonio, Marta ;
Lupon, Josep ;
Galan, Amparo ;
Vila, Joan ;
Urrutia, Agustin ;
Bayes-Genis, Antoni .
AMERICAN HEART JOURNAL, 2012, 163 (05) :821-828
[8]   ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 [J].
Dickstein, Kenneth ;
Cohen-Solal, Alain ;
Filippatos, Gerasimos ;
McMurray, John J. V. ;
Ponikowski, Piotr ;
Poole-Wilson, Philip Alexander ;
Stromberg, Anna ;
van Veldhuisen, Dirk J. ;
Atar, Dan ;
Hoes, Arno W. ;
Keren, Andre ;
Mebazaa, Alexandre ;
Nieminen, Markku ;
Priori, Silvia Giuliana ;
Swedberg, Karl .
EUROPEAN HEART JOURNAL, 2008, 29 (19) :2388-2442
[9]   Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - The Presage™ ST2 assay [J].
Dieplinger, Benjamin ;
Januzzi, James L., Jr. ;
Steinmair, Martin ;
Gabriel, Christian ;
Poelz, Werner ;
Haltmayer, Meinhard ;
Mueller, Thomas .
CLINICA CHIMICA ACTA, 2009, 409 (1-2) :33-40
[10]   Statins in Heart Failure: The Paradox Between Large Randomized Clinical Trials and Real Life [J].
Gastelurrutia, Paloma ;
Lupon, Josep ;
de Antonio, Marta ;
Urrutia, Agustin ;
Diez, Crisanto ;
Coll, Ramon ;
Altimir, Salvador ;
Bayes-Genis, Antoni .
MAYO CLINIC PROCEEDINGS, 2012, 87 (06) :555-560